COPENHAGEN (dpa-AFX) - Novo Nordisk A/S (NVO) announced its agreement to acquire Cardior Pharmaceuticals for 1.025 billion Euros on Monday.
The deal involves an initial payment and potential additional payments upon reaching specific development and commercial milestones.
The acquisition also includes Cardior's primary compound, CDR132L, currently undergoing phase 2 clinical trials for heart failure treatment.
The completion of the acquisition is contingent upon regulatory approvals and the finalization is slated for the second quarter of 2024.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
